THERAPEUTIC OPTIONS IN PREVENTING UTEROPLACENTAL UNIT HYPOXEMIA

Stefan Dugalic,Milos Petronijević

doi:10.24125/sanamed.v13i2.225

Abstract

A miscarriage is primarily defined as an unintentional loss of pregnancy before the 20 th week of gestation. Both the practice and theory show that pregnancy losses up to the 10 th week of gestation may, besides many other gynecological and microbiological causes, also be brought down to the existence of some of the acquired thrombophilia such as antiphospholipid syndrome. Numerous studies have been conducted to examine the efficiency of therapy administration to prevent adverse outcomes of pregnancy. Hereditary thrombophilia are more connected with adverce pregnancy outcomes.

Highlights

A miscarriage is primarily defined as an unintentional loss of pregnancy before the 20th week of gestation, observed both from the aspect of pathophysiology and anatomy
Both the practice and theory show that pregnancy losses up to the 10th week of gestation may, besides many other gynecological and microbiological causes, be brought down to the existence of some of the acquired thrombophilia such as antiphospholipid syndrome
This study has proven that the administration of LMWH in the group with novel thrombophilia has decreased the incidence of IUGR, intrauterine fetal death, as well as preeclampsia

Summary

INTRODUCTION

A miscarriage is primarily defined as an unintentional loss of pregnancy before the 20th week of gestation, observed both from the aspect of pathophysiology and anatomy. Patients with thrombophilia and previous habitual miscarriages, who did not use antithrombotic therapy in the new pregnancy, had an increased risk of sudden fetal death incidence in relation to the group of women who had negative finding to thrombophilia. It is necessary to emphasize that patients with established thrombophilia and new pregnancy but without therapy were not examined The study took this position due to the fact that in vitro data in experimental conditions show that LMWH may be considered a promoter of extravilloustrophoblast development and may stimulate their invasive processes [7, 8]. Clinical studies on the effect of antithrombotic therapy to pregnancy losses have been analyzed in relation to antiphospholipid syndrome (by administration of aspirin or heparin), as well as conditions of thrombophilia by use of different therapy. Even though they prove the positive effects of the therapy, conclude that it is necessary to continue further investigations

CONCLUSION

Findings

DECLARATION OF INTEREST